Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Starting treatment news

Show

From To
Improving Access to Patient Care & Time to Viral Suppression Using HIV Rapid Entry Programs

The CDC has reported that 44% of individuals who are living with HIV are residing in the southern region of the United States; HIV diagnosis rates are higher in the South than they are for Americans overall.

Published
22 March 2018
From
Contagion Live
Average time from HIV diagnosis to treatment fell to six days in 2016 in San Francisco

The average time from HIV diagnosis to treatment initiation in San Francisco shrank from 35 days to six days between 2013 and 2016 as the city implemented

Published
07 March 2018
By
Keith Alcorn
Same-day treatment start improves retention in care and viral suppression in Lesotho

Starting treatment at home, on the day of diagnosis, proved acceptable in rural Lesotho and resulted in improved linkage to care and viral suppression compared with routine

Published
07 March 2018
By
Keith Alcorn
Issue Brief: Suboptimal Immune Recovery on Antiretroviral Therapy

A subset of people on ART experience limited or no recovery of CD4+ T cell counts despite achieving and maintaining undetectable HIV viral loads, and these individuals have an elevated risk of illness and death compared with counterparts who obtain greater CD4+ T cell gains.

Published
06 March 2018
From
TAG
An Exciting Act II for the Study That Proved Treating HIV Early Is Best

With a grant to follow their large study population through 2021, researchers hope to gain vital new insights about HIV infection.

Published
25 February 2018
From
Poz
Darunavir/ritonavir most durable boosted protease inhibitor in European patients, especially those switching treatment for any reason

Darunavir/ritonavir (DRV/r) is the most durable boosted protease inhibitor for antiretroviral therapy (ART)-experienced people, investigators from the EuroSIDA cohort report in HIV Medicine. People switching

Published
13 February 2018
By
Michael Carter
Study finds more than half of patients worldwide don’t access HIV treatment until immune systems are severely compromised

Data from nearly a million patients starting treatment for HIV across the world over the last decade shows 55 percent of them accessed antiretroviral treatment only after their immune cell — or CD4 — counts had dropped below 200, leaving them extremely vulnerable to illnesses and infections.

Published
02 February 2018
From
Science Speaks
GlaxoSmithKline Projects Tough Environment for Triumeq and Tivicay

GlaxoSmithKline is witnessing increased demand for Tivicay as compared to Triumeq. Approximately 40% to 45% of the prescribed Tivicay is used by physicians with Gilead Sciences’ Tenofovir alafenamide (or TAF) therapy, Descovy. The company expects increased competition for its dolutegravir franchise after the launch of Gilead Sciences’ (GILD) integrase inhibitor, bictegravir.

Published
01 February 2018
From
Market Realist
China Introduces Low-Cost, Single-Pill HIV Treatment

Five months after receiving approval from the China Food and Drug Administration, British pharmaceutical giant GlaxoSmithKline (GSK) on Saturday introduced its market-leading antiretroviral drug Triumeq, which contains three active ingredients in a single pill.

Published
24 January 2018
From
Sixth Tone
Immediate HIV Treatment Has Little Impact on Risk of Future Drug Resistance

Starting antiretroviral therapy (ART) immediately rather waiting until a person's CD4 count falls below 500 cells/µL has almost no impact on the person's risk of developing antiretroviral resistance over the next seven years, according to a study published online in the journal AIDS. In this 51,000-person analysis, the impact of immediate ART on acquired drug resistance disappeared almost completely among people starting treatment in 2005 or later.

Published
07 January 2018
From
The Body Pro

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.